Express Mail No. EV 473 971 634 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Michael A. Zeligs

Confirmation No.:

9606

Serial No.:

10/616,477

Art Unit:

1618

Filed:

July 9, 2003

Examiner:

Ebrahim, Nabila G.

For:

Phytochemicals for the Treatment

Attorney Docket No.:

9439-015-999

of Mastalgia, Endometriosis and HPV-related Conditions Including

Cervical Dysplasia

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references A04-A05 and C21-C23 listed on the attached form entitled "List of References Cited by Applicant." Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents (i.e., references A04-A05) are not submitted herewith. Copies of references C21-C23 are submitted herewith.

Identification of the listed reference is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such reference is available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97(c), since this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, but before the mailing of a

NYI-3937777+1

From-7144

final Office Action or Notice of Allowance, a fee of \$180.00 under 37 C.F.R. § 1.17(p) is believed due. Please charge the required fee to Jones Day deposit account no. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date:

January 25, 2007

29,258

(Reg. No.)

JONES DAY

Thomas E. Friebe

222 East 41st Street New York, New York 10017

(212) 326-3939

Exp

press	Mail	No.:	EV	473	97 L	O	14 U	•
					She	ct	l of l	1
							_	

	ATTY. DOCKET NO. 9439-015-999	APPLICATION NO. 10/616,477		
LIST OF REFERENCES CITED BY APPLICANT (Use several shoots if necessary)	APPLICANT Michael A. Zoligs	APPLICANT		
	FILING DATE July 9, 2003	ART UNIT		

U.S. PATENT DOCUMENTS						
*Examiner		Bocument Newber	Date mrs/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Retevant Passages or Retevant Figures Appear	
Enițials	A04	6,399,645	05/04/02	Bell of al.		
	A05	2003/0096855	05/22/03	Zeligs		

FOREIGN PATENT DOCUMENTS						
*Examiner		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentoc or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	B01					
	B02					

	_	NON PATENT LITERATURE DOCUMENTS	
*Examiner		Include mane of the nother (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue anader(s), pathisher, city and/or country where published, serial, symposium, catalog, etc.), date, page(s), volume-issue anader(s), pathisher, city and/or country where published.	T
Initials		scrisk symposium, catalog, etc.), date, page(s), volume-ispue aumber(s), paintaiter, thy successive autolysis products of Brassica Bradfield CA, Bjeldanes LF. Modification of carcinogen metabolism by indolytic autolysis products of Brassica	
	C21		
	C22	George KR Rieldanas LF. Olicomerization of theole-3-carolina in adjustus acros.	
	C22	Chem Res Toxicol. 1992 Mar-Apr;5(2):188-93	_
	C23	Bjeldanes LF, Klm JY, Grose KR, Bartholomew JC, Francisia CA, Administrative States of the CA, 3,7,8- receptor agonists generated from Indole-3-carbinol in vitro and in vivo; comparisons with 2,3,7,8- receptor agonists generated from Indole-3-carbinol in vitro and in vivo; comparisons with 2,3,7,8-	
		Prog Natl Acad Sci U S A. 1991 Nov 1;88(21):9543-7	
	C24		<del> </del>
	C25		-
	C26		├
	C27		
,	C28		<del> </del>
	C29		₩
	C30		
	<b>C31</b>		├
	C32		

	NYI-3944891v2			
	EXAMINER	DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through conformance and not considered. Include copy of this form with next communication to applicant.				